M2 PRESSWIRE-September 5, 2019-: Global Hypoactive
Sexual Desire Disorder (HSDD) Treatment Market Analysis Report, 2017-2019 & 2027
The Food and Drug Administration has approved bremelanotide (Vyleesi) to treat acquired, generalized hypoactive
sexual desire disorder (HSDD) in premenopausal women.
Biopharmaceutical company Palatin Technologies Inc (NYSE American: PTN) reported on Friday the receipt of marketing approval from the US Food and Drug Administration (FDA) for the New Drug Application (NDA) for Vyleesi (bremelanotide injection) for the treatment of premenopausal women with acquired, generalised hypoactive
sexual desire disorder (HSDD), the most common type of female sexual dysfunction in the US.
Food and Drug Administration on Friday gave its approval to Vyleesi, the second medication so far approved to help women with low
sexual desire.
Theologians in the past who conflated
sexual desire and lust or overemphasized the link between sex and procreation reasonably concluded that sex would be either inconsistent with heavenly perfection or just unnecessary But because contemporary Christians have come to see
sexual desire as longing for intimacy and sex as love-making, we are in a better position to consider how it could fit into heavenly life.
Hypoactive
sexual desire disorder (HSDD) is the most common of the female sexual dysfunctions.
A team of psychologists, as part of a research, have concluded that
sexual desire may play a major role -- not only in attracting potential partners to each other -- but also in encouraging the formation of an attachment between them.
AMAG Pharmaceuticals announced that the FDA has accepted its New Drug Application, or NDA, for bremelanotide, a first-in-class melanocortin 4 receptor agonist designed for the treatment of hypoactive
sexual desire disorder, or HSDD, in premenopausal women.
Bremelanotide is a first-in-class melanocortin 4 receptor agonist developed to treat acquired, generalized hypoactive
sexual desire disorder (HSDD) in premenopausal women.
Phase 3 results from the two Reconnect studies of 1,247 premenopausal women with hypoactive
sexual desire disorder in stable relationships showed that bremelanotide was associated with statistically significant improvements in
sexual desire and levels of distress about hyposexuality, compared with placebo.